-
公开(公告)号：US20190201485A1
公开(公告)日：2019-07-04
申请号：US16293379
申请日：2019-03-05
Applicant: The Texas A&M University System
Inventor： Richard H. Gomer , Darrell Pilling , Nehemiah Cox , Tejas R. Karhadkar
IPC: A61K38/17 , A61K9/00 , A61K31/351 , A61P19/04 , A61K31/4192 , A61K31/495
CPC classification number: A61K38/177 , A61K9/0019 , A61K31/196 , A61K31/215 , A61K31/351 , A61K31/4192 , A61K31/495 , A61P11/00 , A61P19/04 , C07K16/40 , Y02A50/401
Abstract: The present disclosure relates to anti-fibrotic sialidase-inhibitor compounds and methods of preventing or inhibiting fibrosis using such compounds. The present disclosure also relates to methods of controlling the formation of fibrocytes or their activity using such compounds. The compounds may include both antibodies as well as small molecules. The methods may involve administering the compounds to a patient with or at risk of developing fibrosis in a manner that inhibits at least one sialidase in the patient.
-
公开(公告)号：US20190192683A1
公开(公告)日：2019-06-27
申请号：US15853427
申请日：2017-12-22
Applicant: BiOasis Technologies, Inc.
Inventor： Wilfred Arthur JEFFERIES
CPC classification number: A61K47/6849 , A61K38/1793 , A61K47/483 , A61K47/64 , A61K47/644 , Y02A50/401 , Y02A50/473
Abstract: Provided are central nervous system (CNS)-targeted antibody or therapeutic Fc-fusion polypeptide conjugates having modified Fc regions, and related methods of use thereof, for instance, to facilitate delivery of therapeutic and/or diagnostic polypeptides across the blood-brain barrier (BBB), and thereby treat and/or diagnose conditions associated with the CNS, including cancer, pain, and various neuropathologies, such as neuroinflammatory, auto-immune, and/or neurodegenerative disorders.
-
公开(公告)号：US20190177330A1
公开(公告)日：2019-06-13
申请号：US16271376
申请日：2019-02-08
Applicant: Magenta Therapeutics Inc.
Inventor： Arthur Glenn Romero
IPC: C07D487/04 , C07D519/00 , C07D471/04 , A61K35/28 , C12N5/0789
CPC classification number: C07D487/04 , A61K35/28 , A61K2035/124 , C07D471/04 , C07D519/00 , C12N5/0647 , C12N2501/999 , Y02A50/401 , Y02A50/414
Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
-
公开(公告)号：US20190119199A1
公开(公告)日：2019-04-25
申请号：US16164517
申请日：2018-10-18
Applicant: Rutgers, The State University of New Jersey
Inventor： Kathryn E. Uhrich , Allison Faig
IPC: C07C233/47 , A61Q19/10 , C07C235/06 , A61K45/06 , A61K31/23 , A61K8/42 , C09D5/14 , A61K9/127 , A61Q17/00
CPC classification number: C07C233/47 , A61K8/42 , A61K9/1272 , A61K31/23 , A61K45/06 , A61Q17/005 , A61Q19/10 , C07C235/06 , C09D5/14 , Y02A50/401 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , A61K2300/00
Abstract: The invention provides an antibacterial compound of formula I: or a salt thereof, as well as an antibacterial compound of formula II: or a salt thereof, wherein R1, R2, X, Y and n have any of the values defined in the specification.
-
公开(公告)号：US20190022029A1
公开(公告)日：2019-01-24
申请号：US16058437
申请日：2018-08-08
Applicant: BioMendics, LLC
Inventor： Chun-che Tsai , Karen M. McGuire , James M. Jamison , Jack L. Summers
IPC: A61K31/05 , A61K8/67 , A61K9/00 , A61K8/60 , A61K8/33 , A61K8/34 , A61Q7/00 , A61Q19/08 , A61K47/40 , A61K47/36 , A61K9/06 , A61K45/06 , A61K31/7034 , A61K31/09 , A61K31/085 , A61K8/73 , A61K9/08 , A61K9/19 , A61K8/70 , A61K31/03 , A61K31/167 , A61K31/375 , A61K31/655
CPC classification number: A61K31/05 , A61K8/33 , A61K8/347 , A61K8/602 , A61K8/676 , A61K8/70 , A61K8/733 , A61K8/738 , A61K9/0019 , A61K9/06 , A61K9/08 , A61K9/19 , A61K31/03 , A61K31/085 , A61K31/09 , A61K31/167 , A61K31/375 , A61K31/655 , A61K31/7034 , A61K45/06 , A61K47/36 , A61K47/40 , A61Q7/00 , A61Q19/08 , Y02A50/401 , A61K2300/00
Abstract: Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CRa═CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.
-
公开(公告)号：US20180305425A1
公开(公告)日：2018-10-25
申请号：US15770965
申请日：2016-10-27
Applicant: University of Massachusetts
Inventor： Sanjay Ram , Douglas T. Golenbock , Alberto Visintin , Jutamas Shaughnessy
CPC classification number: C07K14/472 , A61K38/00 , A61P31/04 , C07K2319/20 , C07K2319/30 , Y02A50/401 , Y02A50/406 , Y02A50/411 , Y02A50/473
Abstract: Fusion proteins comprising human FH domains 18-20 (FH18-20) linked via an optional linker to IgG Fc, wherein the FH has mutation of D to G at position 1119 in domain 19; FHD1119G/Fc), and methods of use thereof, e.g., to treat pathogen infections.
-
公开(公告)号：US20180275126A1
公开(公告)日：2018-09-27
申请号：US15976938
申请日：2018-05-11
Applicant: Virginia Commonwealth University
Inventor： Richard T. MARCONI , Christopher EARNHART , Lee D. OLIVER
IPC: G01N33/569 , C07K16/12 , A61K39/02
CPC classification number: G01N33/56911 , A61K39/0225 , A61K2039/55505 , A61K2039/55566 , A61K2039/70 , C07K14/20 , C07K16/1207 , C07K2317/34 , C07K2317/734 , C07K2319/00 , C07K2319/21 , C07K2319/22 , G01N2333/20 , G01N2469/20 , Y02A50/401 , Y02A50/57
Abstract: Chimeric polyvalent recombinant proteins for use as vaccines and diagnostics for Lyme disease (e.g. in canines and humans) are provided. The chimeric proteins comprise epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types and/or OspE types. The OspC types may be associated with mammalian Borrelia infections.
-
公开(公告)号：US20180238874A1
公开(公告)日：2018-08-23
申请号：US15957312
申请日：2018-04-19
Applicant: BIOMERIEUX
Inventor： Lionel LEVET , Odile MEJAN-LETOURNEUR
IPC: G01N33/569 , C07K16/42 , C07K14/20
CPC classification number: G01N33/56911 , A61K39/00 , C07K14/195 , C07K14/20 , C07K16/4233 , C07K2319/40 , G01N2333/20 , G01N2469/20 , Y02A50/401 , Y02A50/57
Abstract: Chimera proteins includlng: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) at least one sequence of an OspC protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.
-
9.发明申请
公开(公告)号：US20180228772A1
公开(公告)日：2018-08-16
申请号：US15949335
申请日：2018-04-10
Applicant: Allergan, Inc.
Inventor： Richard L. Beard , Tien T. Duong , John E. Donello , Veena Viswanath , Michael E. Garst
IPC: A61K31/417 , C07D233/64 , C07C317/50 , C07C275/30 , C07C323/44 , C07C317/42 , A61K31/198 , A61K31/17 , C07K5/072 , C07K5/062 , C07K5/078 , A61K31/216 , A61K31/197 , A61K31/4045 , C07C323/60 , C07D209/20
CPC classification number: A61K31/417 , A61K31/17 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/4045 , C07C275/30 , C07C317/42 , C07C317/50 , C07C323/44 , C07C323/60 , C07D209/20 , C07D233/64 , C07K5/06017 , C07K5/06034 , C07K5/06052 , C07K5/0606 , C07K5/06113 , C07K5/06147 , C07K5/06156 , Y02A50/401
Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
-
公开(公告)号：US20180200346A1
公开(公告)日：2018-07-19
申请号：US15850371
申请日：2017-12-21
Applicant: Albumedix A/S
Inventor： David James Ballance , Darrell Sleep
IPC: A61K38/48 , C12N15/62 , A61K47/65 , C12N9/96 , A61K9/00 , A61K38/21 , A61K38/38 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/715 , C07K14/76 , C07K14/765 , A61K47/42 , A61K48/00 , A61K39/00
CPC classification number: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
